Fgl2: Link between hepatitis B and SARS?

Drug Discovery Today

Volumn 8, Issue 17, 2003, Pages 768-770

  Robertson, Morag ^a  

^a NONE

Author keywords

Clotting; Drug Discovery; Fibroleukin; Hepatitis B; Pharmaceutical Science; SARS; Thrombin; Virology

Indexed keywords

BLOOD CLOTTING FACTOR; CD8 ANTIGEN; FIBRINOGEN VARIANT; FIBROLEUKIN PROTHROMBINASE; GAMMA INTERFERON; UNCLASSIFIED DRUG;

CORONAVIRUS; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DISEASE; NONHUMAN; NOTE; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSCRIPTION INITIATION; VIRUS PNEUMONIA;

EID: 0042433135     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02836-8     Document Type: Short Survey

References (5)

1. Marsden P.A., et al. The Fgl2/fibroleukin prothrombase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J. Clin. Invest. 112:2003;58-66.
2. Maupas P., Melnick J.L. Hepatitis B infection and primary liver cancer. Prog. Med. Virol. 27:1981;1-5.
3. Hoofnagle J.H., di Bisceglie A.M. The treatment of chronic viral hepatitis. New Engl. J. Med. 336:1997;347-356.
4. Rich J.D., et al. A review of the case for hepatitis B vaccination of high-risk adults. Am. J. Med. 114:2003;316-318.
5. Peiris J.S.M., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 361:2003;1767-1772.